Italian Social Tariffs For QALYs Calculation Are Now Available

Published Jun 17, 2013
Milano and Napoli, Italy - The Italian health care system is starting to take information on HRQoL and QALYs into consideration when deciding on the utilization of available resources. Although comparisons of different national value sets have demonstrated the existence of country specificity of utilities, in Italy, a specific value set was still missing.  In the study “Italian Population-Based Values of EQ-5D Health States,” published in Value in Health, researchers from Milan and Napoli created the first Italian general population EQ-5D value set, thus offering the possibility of its use in cost-utility analyses targeted at the Italian health care system. In their study, authors Scalone et.al, estimated the first value set for the calculation of Italian-specific QALYs, based on preferences elicited on EQ-5D health states using the time trade-off technique. They followed the Standard EuroQoL Measurement and Valuation of Health (MVH) protocol revised in 2009, and involved a sample of the Italian general adult population representative of age, gender and geographical distribution. By investigating several regression models, the researchers were able to determine which one provides the most logically consistent estimates and with a good level of statistical efficiency. Lorenzo Mantovani, DSc, Senior Researcher at the Department of Clinical Medicine and Surgery, Federico II University of Naples, says, “With the publication of this study, Italian researchers and policy makers will be able to use QALYs calculated with the standard reference tool EQ-5D, finally, based on Italian-specific social tariffs.” The study was financed by the EuroQol and CHARTA Foundations.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

Promoting Fairness in Funding Decisions

Jun 24, 2026

Value in Health announced the publication of a special themed section of research papers that offer new tools to help health policy makers weigh fairness alongside cost-effectiveness when deciding which treatments and programs to fund.

Listening to Patients in the Real World

Jun 23, 2026

Value in Health, the official journal of ISPOR announced today the publication of an ISPOR Good Practices Report outlining 9 areas to strengthen the robustness, transparency, and feasibility of real-world patient-reported outcomes studies.

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×